Country- and age-specific optimal allocation of dengue vaccines

Journal of Theoretical Biology

Volumn 342, Issue , 2014, Pages 15-22

  Ndeffo Mbah, Martial L ^a   Durham, David P ^a   Medlock, Jan ^b   Galvani, Alison P ^a  

^a YALE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Dengue hemorrhagic fever; Dengue vaccine; Mathematical modeling; Optimization

Indexed keywords

DENGUE VACCINE;

DENGUE FEVER; DISEASE TRANSMISSION; NUMERICAL MODEL; OPTIMIZATION; VACCINATION; VACCINE;

AGE DISTRIBUTION; ARTICLE; BRAZIL; DEMOGRAPHY; DENGUE; DENGUE VIRUS; DISEASE TRANSMISSION; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; INCIDENCE; MASS IMMUNIZATION; MATHEMATICAL MODEL; MORBIDITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SEROTYPE; SOUTH AND CENTRAL AMERICA; SOUTHEAST ASIA; THAILAND; VACCINE PRODUCTION;

BRAZIL; LATIN AMERICA; THAILAND;

DENGUE HEMORRHAGIC FEVER; DENGUE VACCINE; MATHEMATICAL MODELING; OPTIMIZATION;

ADULT; AGING; ASIA, SOUTHEASTERN; DENGUE; DENGUE VACCINES; GEOGRAPHY; HUMANS; LATIN AMERICA; MASS VACCINATION;

EID: 84887137634     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.10.006     Document Type: Article

References (56)

1. Amarasinghe A., Mahoney R.T. Estimating potential demand and supply of dengue vaccine in Brazil. Hum. Vaccin. 2011, (Jul;7(7):776-80. PubMed PMID: 21734468. Pubmed Central PMCID: 3225768. Epub 2011/07/08. eng).
2. Amarasinghe A., Wichmann O., Margolis H.S., Mahoney R.T. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum. Vaccin. 2010, 6(9):745.
3. Andraud M., Hens N., Marais C., Beutels P. Dynamic Epidemiological Models for Dengue Transmission: A Systematic Review of Structural Approaches. PLoS One 2012, 7(11):e49085.
4. Balmaseda A., Hammond S.N., Tellez Y., Imhoff L., Rodriguez Y., Saborío S.I., et al. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop. Med. Int. Health 2006, 11(6):935-942.
5. Beatty M.E., Beutels P., Meltzer M.I., Shepard D.S., Hombach J., Hutubessy R., et al. Health economics of dengue: A systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 2011, 84(3):473-488.
6. Boggs P.T., Tolle J.W. Sequential quadratic programming for large-scale nonlinear optimization. J. Comput. Appl. Math. 2000, 124(1):123-137.
7. Carrasco L.R., Lee L.K., Lee V.J., Ooi E.E., Shepard D.S., Thein T.L., et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Neglected Trop. Dis. 2011, 5(12):e1426.
8. Chanthavanich P., Luxemburger C., Sirivichayakul C., Lapphra K., Pengsaa K., Yoksan S., et al. Immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg. 2006, 75(1):26-28.
9. Chao D.L., Halstead S.B., Halloran M.E., Longini I.M. Controlling dengue with vaccines in Thailand. PLoS Negl. Trop. Dis. 2012, 6(10):e1876.
10. Chareonsook O., Foy H.M., Teeraratkul A., Silarug N. Changing epidemiology of dengue hemorrhagic fever in Thailand. Epidemiol. Infect. 1999, 122(1):161-166.
11. Coudeville L., Garnett G.P. Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS One 2012, 7(12):e51244.
12. Crovello T.J., Hacker C.S. Evolutionary strategies in life table characteristics among feral and urban strains of Aedes aegypti (L.). Evolution 1972, 185-196.
13. Cummings D.A.T., Iamsirithaworn S., Lessler J.T., McDermott A., Prasanthong R., Nisalak A., et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med. 2009, 6(9):e1000139.
14. Durham D., Ndeffo Mbah M., Medlock J., Luz P., Meyers L., Paltiel A., et al. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31(37):3957-3961.
15. Economic UNDo, 2006. World Population Prospects: The 2004 Revision. Volume I Comprehensive Tables. United Nations Publications.
16. Endy T.P., Chunsuttiwat S., Nisalak A., Libraty D.H., Green S., Rothman A.L., et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 2002, 156(1):40-51.
17. Focks D.A., Daniels E., Haile D.G., Keesling J.E. A simulation model of the epidemiology of urban dengue fever: literature analysis, model development, preliminary validation, and samples of simulation results. Am. J. Trop. Med. Hyg. 1995, 53(5):489-506.
18. Group W-VDVM Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl. Trop. Dis. 2012, 6(3):e1450.
19. Guzmán M.G., Kouri G., Bravo J., Valdes L., Susana V., Halstead S.B. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 2002, 6(2):118-124.
20. Halstead S.B. Dengue in the Americas and Southeast Asia: do they differ?. Rev. Panam. de Salud Pública 2006, 20(6):407-415.
21. Halstead S.B. Dengue. Lancet 2007, 370(9599):1644-1652.
22. Halstead S.B. Dengue vaccine development: a 75% solution?. Lancet 2012, (Nov 3;380(9853):1535-1536. PubMed PMID: 22975339. Epub 2012/09/15. eng).
23. Harrington L.C., Edman J.D., Scott T.W. Why do female Aedes aegypti (Diptera: Culicidae) feed preferentially and frequently on human blood?. J. Med. Entomol. 2001, 38(3):411-422.
24. Hartley L., Donnelly C., Garnett G. The seasonal pattern of dengue in endemic areas: mathematical models of mechanisms. Trans. R. Soc. Trop. Med. Hyg. 2002, 96(4):387-397.
25. Hollingsworth T.D., Klinkenberg D., Heesterbeek H., Anderson R.M. Mitigation strategies for pandemic influenza a: balancing conflicting policy objectives. PLoS Comput. Biol. 2011, 7(2):e1001076.
26. Honório N.A., Nogueira R.M.R., Codeço C.T., Carvalho M.S., Cruz O.G., Magalhães, et al. Spatial evaluation and modeling of dengue seroprevalence and vector density in Rio de Janeiro, Brazil. PLoS Negl. Trop. Dis. 2009, 3(11):e545.
27. Johansson M.A., Hombach J., Cummings D.A.T. Models of the impact of dengue vaccines: A review of current research and potential approaches. Vaccine 2011, 29(35):5860-5868.
28. Klepac P., Laxminarayan R., Grenfell B.T. Synthesizing epidemiological and economic optima for control of immunizing infections. Proc. Natl. Acad. Sci. 2011, 108(34):14366-14370.
29. Lee B.Y., Connor D.L., Kitchen S.B., Bacon K.M., Shah M., Brown S.T., et al. Economic Value of Dengue Vaccine in Thailand. Am. J. Trop. Med. Hyg. 2011, 84(5):764-772.
30. Luz P.M., Vanni T., Medlock J., Paltiel A.D., Galvani A.P. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet 2011, 377(9778):1673-1680.
31. Murphy B.R.W.S. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 2011, 29(1):587-619.
32. Murrell S., Wu S.C., Butler M. Review of dengue virus and the development of a vaccine. Biotechnol. Adv. 2011, 29(2):239-247.
33. Nagao Y., Koelle K. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc. Natl. Acad. Sci. 2008, 105(6):2238-2243. (2008 February 12).
34. Ndeffo Mbah M.L., Gilligan C.A. Resource allocation for epidemic control in metapopulations. PLoS One 2011, 6(9):e24577.
35. Nisalak A., Endy T.P., Nimmannitya S., Kalayanarooj S., Scott R.M., Burke D.S., et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am. J. Trop. Med. Hyg. 2003, 68(2):191-202.
36. Nocedal J., Wright S. Numerical Optimization 2006, Springer.
37. Peeling R.W., Artsob H., Pelegrino J.L., Buchy P., Cardosa M.J., Devi S., et al. Evaluation of diagnostic tests: dengue. Nat. Rev. Microbiol. 2010, 8:S30-S38.
38. Rodriguez-Barraquer I., Cordeiro M.T., Braga C., de Souza W.V., Marques E.T., Cummings D.A.T. From re-emergence to hyperendemicity: the natural history of the dengue epidemic in Brazil. PLoS Negl. Trop. Dis. 2011, 5(1):e935.
39. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, (0).
40. San Martín J.L., Brathwaite O., Zambrano B., Solórzano J.O., Bouckenooghe A., Dayan G.H., et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am. J. Trop. Med. Hyg. 2010, 82(1):128-1235.
41. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine 2011, 29(42):7276-7284.
42. Scott T.W., Naksathit A., Day J.F., Kittayapong P., Edman J.D. A fitness advantage for Aedes aegypti and the viruses it transmits when females feed only on human blood. Am. J. Trop. Med. Hyg. 1997, 57(2):235-239.
43. Scott T.W., Amerasinghe P.H., Morrison A.C., Lorenz L.H., Clark G.G., Strickman D., et al. Longitudinal studies of Aedes aegypti (Diptera: Culicidae) in Thailand and Puerto Rico: blood feeding frequency. J. Med. Entomol. 2000, 37(1):89-101.
44. Shekhar K.C., Huat O.L. Epidemiology of dengue/dengue hemorrhagic fever in Malaysia-a retrospective epidemiological study 1973-1987. Part I: dengue hemorrhagic fever (DHF). Asia Pac J Public Health 1992, 6(2):15-25. (PubMed PMID: 1308765. Epub 1992/01/01. eng).
45. Shepard D.S., Coudeville L., Halasa Y.A., Zambrano B., Dayan G.H. Economic impact of dengue illness in the Americas. Am. J. Trop. Med. Hyg. 2011, 84(2):200-207.
46. Siqueira J.B., Martelli T.M.C., Coelho G.E., da Rocha Simplício A.C., Hatch D.L. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg. Infect. Dis 2005, 11(1):48-53.
47. Srikiatkhachorn A., Gibbons R.V., Green S., Libraty D.H., Thomas S.J., Endy T.P., et al. Dengue Hemorrhagic Fever: The Sensitivity and Specificity of the World Health Organization Definition for Identification of Severe Cases of Dengue in Thailand, 1994-2005. Clin. Infect. Dis. 2010, 50(8):1135-1143.
48. Sriprom M., Pongsumpun P., Yoksan S., Barbazan P., Gonzalez J., Tang I. Dengue haemorrhagic fever in thailand, 1998-2003: primary or secondary infection. Dengue Bull. 2003, 27:39-45.
49. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull. WHO 2005, 83(4):308-314.
50. Styer L.M., Minnick S.L., Sun A.K., Scott T.W. Mortality and reproductive dynamics of Aedes aegypti (Diptera: Culicidae) fed human blood. Vector-Borne Zoonotic Dis. 2007, 7(1):86-98.
51. Suaya J.A., Shepard D.S., Siqueira J.B., Martelli C.T., Lum L.C.S., Tan L.H., et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am. J. Trop. Med. Hyg. 2009, 80(5):846-855.
52. Teixeira M.G.C.M., Coelho G., Barreto M.L. Recent shift in age pattern of dengue hemorrhagic fever. Brazil. Emerg. Infect. Dis. 2008, 14(10):1663.
53. Watson M. Dengue vaccine roll-out: getting ahead of the game. Bull. WHO 2011, 89:476-477.
54. Watts D.M., Burke D.S., Harrison B.A., Whitmire R.E., Nisalak A. Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. DTIC Doc. 1986.
55. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5(7):518-528.
56. Whitehorn J., Farrar J. Dengue. Br. Med. Bull. 2010, 95(1):161-173.